Drug developers should use a “model-informed drug discovery and development” program, which can help developers simplify the protocol design process, says Michael Krams, chief quantitative medicine officer at Exscientia.
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests:
What topics interest you? (Check all that apply.)